Adverse renal effects of anti-inflammatory agents: Evaluation of selective and nonselective cyclooxygenase inhibitors

Journal of Internal Medicine

Volumn 253, Issue 6, 2003, Pages 643-652

  Gambaro, Giovanni ^a,c   Perazella, M A ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cyclooxygenase; Hypertension; Nonsteroidal anti inflammatory drugs; Oedema; Renal failure

Indexed keywords

ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IRBESARTAN; LEUKOTRIENE; LISINOPRIL; NAPROXEN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB;

ACUTE KIDNEY FAILURE; ANIMAL TISSUE; BLOOD PRESSURE; EVALUATION; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; HYPERKALEMIA; HYPONATREMIA; INTERSTITIAL NEPHRITIS; KIDNEY CANCER; KIDNEY PAPILLA NECROSIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; EDEMA; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION, RENAL; ISOENZYMES; KIDNEY; KIDNEY FAILURE, ACUTE; LEUKOTRIENES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS;

EID: 0038695146     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2003.01146.x     Document Type: Review

References (62)

1. Wallace JL, Chapman K. McKnight W. Limited anti-inflammatory efficacy of cyclooxygenase-2 inhibition in carrageenan-airpouch inflammation. Br J Pharmacol 1999: 126: 1200-4.
2. Parente L, Perretti M. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol 2003; 65: 153-9.
3. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94: 2504-10.
4. Yang T, Singh I, Pham H et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 1998; 274: F481-9.
5. Hartner A, Goppelt-Struebe M, Hilgers KF. Coordinate expression of cyclooxygenase-2 and rennin in the rat kidney in renovascular hypertension. Hypertension 1998; 31: 201-5.
6. Traynor TR, Smart A, Briggs JP, Schnermann J. Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2. Am J Physiol 1999; 277: F706-10.
7. Vio CP, Cespedes C, Gallardo P. Masferrer JL. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension 1997; 30: 687-92.
8. Ferreri NR, An S-J, McGiff JC. Cyclooxygenase-2 expression and function in the medullary thick ascending limb. Am J Physiol 1999; 277: F360-8.
9. Ferguson S, Hébert RL, Laneuville O. NS-398 upregulates constitutive cyclooxygenase-2 expression in the M-1 cortical collecting duct cell line. J Am Soc Nephrol 1999: 10: 2261-71.
10. Abassi Z, Brodsky S, Gealekman O, Rubinstein I, Hoffman A. Winaver J. Intrarenal expression and distribution of cyclo-oxygenase isoforms in rats with experimental heart failure. Am J Physiol Renal Physiol 2001; 280: F43-F53.
11. Nantel F, Meadows E, Denis D, Connolly B, Metters KM, Giaid A. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett 1999: 457: 475-7.
12. Komhoff M, Seyberth HW, Nusing RM, Breyer MD. Cyclooxygenase-2 expression is associated with the macula densa in kidneys from patients with Bartter like syndrome. J Am Soc Nephrol 1999; 10: 437A.
13. Komhoff M, Grõne H-J, Klein T, Seyberth HW, Nûsing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997; 272: F460-8.
14. Catella-Lawson F, McAdam B. Morrison BW et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance. hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735-41.
15. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106(5B): 13S-24S.
16. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66: 76-84.
17. Swan SK, Rudy DW, Lasseter KC et al. Effect of eyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000; 133: 1-9.
18. FDA Arthritis Advisory Committee. Celebrex: Briefing Document: Renal Effects, 1998 Available at: http://www.fda.gov/cder/foi/adcomm/98/celebrex.htm
19. Whelton A, Schulman G, Wallemark C et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Int Med 2000; 160: 1465-70.
20. Breyer MD, Harris RC. Cyclooxygenase 2 and the kidney. Curr Opin Nephrol Hypertens 2001; 10: 89-98.
21. Kammerl MC, Nusing RM, Richthammer W, Kramer BK, Kurtz A. Inhibition of COX-2 counteracts the effects of diuretics in rats. Kidney Int 2001; 60: 1684-91.
22. Gertz BJ, Krupa D, Bolognese JA, Sperling RS, Reicin A. A comparison of adverse renovascular experiences among osteoartritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. Curr Med Res Opin 2002; 18: 82-91.
23. Osterhaus JT, Burke TA, May C, Wentworth C, Whelton A, Bristol S. Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. Clin Ther 2002; 24: 969-89.
24. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE. Verburg KM. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Therapeut 2001; 8: 85-95.
25. Collantes E, Curtis SP, Wing Lee K et al. A multinational randomized controlled clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Family Prac 2002; 3: 1-10 (available from. http://www.biomedcentral.com/1471-2296/3/10).
26. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal drugs. Am J Med 2001; 111: 64-7.
27. Hay E. Derazon H, Bukish N. Katz L, Kruglyakov I. Armoni M. Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor. ACE inhibitor and potassium rich diet. J Emerg Med 2002: 22: 349-52.
28. Silverstein FE, Faich G. Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomised controlled trial. JAMA 2000; 284: 1247-55.
29. Kistler T, Ambuhl PM. Renal safety of combined cyclooxygenase 2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild Volume depletion. Swiss Med Wkly 2001; 131: 193-8.
30. Llinás MT, López R. Rodríguez F, Roig F, Salazar FJ. Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine. Am J Physiol Renal Physiol 2001; 281: F975-82.
31. Bosch-Marce M, Claria J, Titos E et al. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with as cites. Gastroenterology 1999; 116: 1167-75.
32. Rocha JL, Fernandez-Alonso J. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor. rofecoxib. Lancet 2001; 357: 1956-7.
33. Henao J, Hisamuddin I, Nzerue CM, Vasandani G, Hewan-Lowe K. Celecoxib-induced acute interstitial nephritis. Am J Kidney Dis 2002; 39: 1313-7.
34. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153: 477-84.
35. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 153: 477-84.
36. De Leeuw PW. Nonsteroidal ant-inflammatory drugs and hypertension. The risks in perspective, Drugs 1996; 51: 179-87.
37. Johnson AG. NSAIDs and blood pressure. Clinical importance for older patients. Drugs Aging 1998; 12: 17-27.
38. Johnson AG, Nguyen TV, Owe-Young R, Williamson DJ, Day RO. Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-1. J Hum Hypertens 1996; 10: 257-61.
39. Hocherl K, Endemann D, Kammerl MC. Grobecker HF, Kurtz A. Cyclo-oxygenase-2 inhibition increases blood pressure in rats. Br J Pharmacol 2002; 136: 1117-26.
40. Muscara MN, Vergnolle N, Lovren F et al. Selective cyclooxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol 2000: 129: 1423-30.
41. Vioxx® (package insert). Whitehouse Station. NJ: Merck. Inc., March 2000 (Cited by Whelton 2001).
42. FDA Arthritis Advisory Committee. Cardiovascular safety review of rofecoxib, Available at http://www.fda.gov/ohrms/ac/01/briefing/367762 -06_cardio.pdf.2001.
43. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 2002; 287: 64-71.
44. Schwartz JI, Vandormael K, Malice MP et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002; 72: 50-61.
45. Reitblat T, Zamir D, Estis L, Priluk R, Drogenikov T, Viskoper JR. The different patterns of blood pressure elevation by rofecoxib and nabumetone: J Hum Hypertens 2002; 16: 431-4.
46. White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002; 39: 929-34.
47. Graves JW, Hunder IA. Worsening of hypertension by cyclooxygenase-2 inhibitors. J Clin Hypertens 2000; 2: 396-8.
48. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlortalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967-75.
49. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
50. Hypertension Detection and Follow-up Program Cooperative Group. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris: 5-year findings of the Hypertension Detection and Follow-up Program. Hypertension 1984; 6: 1198-206.
51. Nickerson-Nutter CL, Medvedeff ED. The effects of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Arthritis Rheumatism 1996; 39: 515-21.
52. Shastri S, McNeill JR. Wilson TW, Poduri R, Kaul C. Gopalakrishnan V. Cysteinyl leukotrienes mediate enhanced vasoconstriction to angiotensin II but not endothelin-1 in SHR. Ant J Physiol Heart Circ Physiol 2001; 281: H342-9.
53. Gulbins E, Parekh N, Rauterberg EW, Schlottmann K, Steinhausen M. Cysteinyl leukotriene actions on the microcirculation of the normal and split hydronephrotic rat kidney. Eur J Clin Invest 1991; 21: 184-96.
54. Tanaka T, Kita T, Tanaka N. The role of peptide leukotrienes in renal failure induced by a tourniquet. Forensic Sci Int 1994; 67: 89-101.
55. Nakamura H, Hishinuma T, Suzuki N et al. Difference in urinary 11-dehydro TXB2 and LTE4 excretion in patients with rheumatoid arthritis. Prostaglandins Leukot Essent Fatty Acids 2001; 65: 301-6.
56. Nasser SM, Patel M, Bell GS, Lee TH. The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma. Am J Respir Crit Care Med 1995; 151: 1326-30.
57. Clish CB, Sun YP, Serhan CN. Identification of dual cyclooxygenase-eicosanoid oxidoreductase inhibitors: NSAIDs that inhibit PG-LX reductase/LTB (4) dehydrogenase. Biochem Biophys Res Commun 2001; 288: 868-74.
58. Bing RJ, Lomnicka M. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? J Am Coll Cardiol 2002; 39: 521-2.
59. Miyataka M, Rich KA, Ingram M, Yamamoto T, Bing RJ. Nitric oxide, anti-inflammatory drugs on renal prostaglandins and cyclooxygenase-2. Hypertension 2002; 39: 785-9.
60. Celotti F, Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol Res 2001; 43: 429-36.
61. Algate DR, Augustin J. Atterson PR et al. General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H- pyrrolizine-5-yl]-acetic acid in experimental animals. Arzneimittel-Forsching 1995; 45: 159-65.
62. Jones R. Efficacy and safety of COX 2 inhibitors. BMJ 2002; 325: 608-9.